Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Sponsor: TIO Discovery Engine
Listed as NCT04521413, this PHASE1/PHASE2 trial focuses on Advanced Solid Malignancies and remains ongoing. Sponsored by TIO Discovery Engine, it has been updated 15 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Jun 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 10 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TIO Discovery Engine
- Treadwell Therapeutics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .